Influenza A H1N1 2009 vaccine in juvenile dermatomyositis reduced immunogenicity in patients under immunosuppressive therapy
proved view Board, and informed consent was by the Local Institutional Re-obtained legal from all participants tered guardian. NCT01151644.
at clinicaltrials.gov The study was or their under regis-no. A single intramuscular dose (0.5 ml) of H1N1 vaccine (A/California/7/2009/Butantan A/California/7/2009-like virus Institute/Sano tered Pasteur) was adminis-controls were evaluated on the day of to all participants. Patients and vaccination (from March 22nd2nd to April ples ) and after three weeks. Blood sam-pant were after vaccination.
immediately obtained before from each and 21 partici-days Vaccine
A inactivated, novel monovalent, supplied split-virus non-adjuvanted, vaccine was Pasteur by Butantan Institute/Sano cine (São Paulo, Brazil). The vac-in uenza contained magglutinin virus with an inactivated 15 μg of split hae-A/California/7/2009 antigen equivalent to the like strain (NYMCx-179A), one of the (H1N1) virus-candidate recommended reassortant vaccine nated chicken eggs were employed us-by the WHO. Embryo-viruses ing the the same standard techniques inactivated in uenza vaccine. The vac-production of seasonal, trivalent, for cine was presented in 5-ml multi-dose vials with thimerosal (45 μg per 0.5-ml dose) as a preservative.
Haemagglutination inhibition assay The California/7/2009-like virus were eval-antibody levels against H1N1 A/uated using the haemagglutination inhi-bition Institute. Sera were tested for antibod-assay (HIA) at the Adolfo Lutz ies in uenza to the Institute strain H1N1 supplied A/California/7/2009 by and calculation at a at nal an initial dilution Butantan of 1:10, had an assigned value of 1:5, and titers purpose, dilution negative of 1:2560. titers For greater than 1:2560 a value of 1:2560. Samples geometric mean values were used in the were tested in duplicate, and analysis. Virus concentrations were pre-viously antigen titration, and the HIA test was determined by haemagglutinin performed after removing naturally oc-
curring nonspeci c inhibitors from the sera as previously described (20).
The vaccination immunogenicity end-points (SP) were the seroprotection after conversion rate (antibody titre ≥1:40), sero-titre titre <1:10 (SC) and rate (pre-vaccination ≥1:10 and ≥4-fold increase in post-vac-≥1:40 or post-vaccination pre-vaccination HIA titre cination (GMTs), titre), geometric mean (GMT of the ratio of antibody titres af-and factor increase in GMT titres ter and before vaccination).
Safety assessment
On parents the day diary card containing the following list were of given vaccination, a 21-day patients personal or of reactions pre-de ned adverse events: local itching) (pain, redness, swelling, and (arthralgia, and sore orrhoea, throat, fever, systemic adverse events cough, headache, diarrhoea, myalgia, ticipants and responses were nasal asked congestion). rhin-to give ‘yes/no’ Par-return evaluation day (21 days after vaccina-their to diary each cards side at effect the and second to tion). Adverse events that were not on the list were also reported. All local re-actions in uenza A H1N1/2009 vaccine, while were considered related to the systemic adverse events were analysed by the investigators to determine their causality. de ned tion or death.
as Severe those requiring adverse events hospitalisa-were Disease activity, JDM clinical course, muscle strength and treatment in JDM patients
JDM activity score (DAS) (21) (range 0–20), activity was assessed by disease and childhood muscle strength was evaluated by (CMAS) ual (22) myositis assessment scale 0–80). muscle (range 0–52) and man-classi ed in monophasic, recurrent and The testing JDM clinical (MMT) course (23) (range was chronic (24). The serum muscle enzymes performed ferase (AST) (normal value <41 IU/L), were aspartate aminotrans-alanine aminotransferase (ALT) (normal value <37 IU/L), lactate dehydrogenase (LDH) creatine (normal range 240–480 IU/L), range 39–308 IU/L) and aldolase (nor-phosphokinase (CK) (normal 585
mal value <7.6 IU/L). Data concerning the prednisone, current JDM treatments included: chloroquine, methotrexate, azathioprine, phamide, mycophenolate mofetil, intra-cyclosporine, cyclophos-venous immunoglobulin and rituximab. Statistical analysis
The immunogenicity and safety analy-ses were descriptive, and the two-sided 95% con dence intervals (CI) were cal-culated assuming binomial distributions for dichotomous variables and log-nor-mal inhibition distribution tinuous variables was based on distribu-titres. for The haemagglutination analysis of con-tional in GMT were compared between JDM assumptions. The GMTs and FI patients and the healthy controls using a Whitney U-test on the logtwo-sided Student’s t-test or Mann-titres. used Mann-Whitney 10-transformed muscle enzymes, JDM scores and pred-to compare demographic U-test was data, also nisone with current categorical and without dose seroconversion.between patients For maries included the rates of seroconver-variables, statistical sum-sion that were compared using Fisher’s exact test. All tests were two-sided with Results
Demographic data
JDM patients and healthy controls had similar current age (15.5 [9–21] [9–21] cies pof years, female pgender =0.511) (63% and vs.frequen-vs. 15 of JDM was 5.5 (2–17) years. =0.286). The median disease duration 41%, Response to immunisation in JDM patients and controls
Table roconversion, I illustrates creases GMTs seroprotection, and factor se-in-and controls before and after in uenza in the GMTs in JDM patients A H1N1/2009 vaccination. Prior to im-munisation, the seroprotection rate and GMT patients and healthy controls (were comparable between JDM pnisation, =0.817; respectively). p=0.457, signi cantly the seroconversion After immu-compared lower in JDM rate was 95% 95% CI CI 94.1% 74.9% to healthy to to controls patients (86.7%, 100.9%, 99.3% vs.p=0.044),
97.5%,
Influenza (the flu)_英语学习_外语学习_教育专区。流感预防Influenza (the flu) By Salwa Hassan Teama Ain Shams University Difference Between Cold or FLU ...
流感病毒与流感疫苗 - Influenza and Influenza Vaccines_生物学_自然科学_专业资料。流感病毒与流感疫苗 - Influenza and Influenza Vaccines...
Influenza (Flu) What Everyone Should Know About Flu and the Flu Vaccine What is the flu? The flu is a contagious respiratory illness caused by ...
Influenza Miley ClassB Influenza, commonly referred to as the flu, is an infectious disease caused by RNA viruses of the family Orthomyxoviridae (the ...
Influenza (flu): ? is a highly infectious viral disease caused by various types of influenza viral strains ? Seasonal Influenza In Hong Kong, the ...
42页 免费 Influenza 32页 10财富值搜你所想,读你所爱 拒绝盗版,营造绿色文库 如要投诉违规内容,请到百度文库投诉中心;如要提出功能问题或意见建议,请点击...
www.themegallery.com Spring - prone diseases Epidemic cerebrospinal meningitis、 、 influenza , mumps and other respiratory diseases流脑、流感、流腮等呼吸道...
Summer 2008 Workshop in Biology and Multimedia for High School Teachers INFLUENZA VIRUS: A Model for Learning About Disease Laurie St.Pierre Sandwich High...
流行性感冒病毒 influenza virus 流行性感冒病毒(influenza virus)简称流感 病毒。按病毒核蛋白(nucleocapside protein,NP) 和基质蛋白(matrix protein, M)分成甲(A)...
流行性感冒 influenza 定义:流行性感冒简称流感,是 由流行性感冒病毒引起的急性呼 吸道传染病。 特征:病毒极易变异; 传染性强; 全身症状重; 呼吸道症状轻。 ...
热门文档